Native Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.70 M
- Paid Up Capital ₹ 0.69 M
- Company Age 34 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
- Satisfied Charges ₹ 1.03 Cr
- Revenue Growth -38.69%
- Profit Growth -33.57%
- Ebitda 0.57%
- Net Worth 9.14%
- Total Assets -4.79%
About Native Drugs
Native Drugs Private Limited (NDPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 February 1990 and has a history of 34 years and 11 months. Its registered office is in Amritsar, Punjab, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.70 M and a paid-up capital of Rs 0.69 M.
The company currently has active open charges totaling ₹5.00 M. The company has closed loans amounting to ₹1.03 Cr, as per Ministry of Corporate Affairs (MCA) records.
Usha Aggarwal and Ashok Aggarwal serve as directors at the Company.
Company Details
-
Location
Amritsar, Punjab, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74899PB1990PTC047094
-
Company No.
047094
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Feb 1990
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Native Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Usha Aggarwal
|
Director | 24-May-2002 | Current |
|
Ashok Aggarwal
|
Director | 24-May-2002 | Current |
Financial Performance of Native Drugs.
Native Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 38.69% decrease. The company also saw a substantial fall in profitability, with a 33.57% decrease in profit. The company's net worth moved up by a moderate rise of 9.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Native Drugs?
Unlock access to Native Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹5.00 M
₹10.28 M
Charges Breakdown by Lending Institutions
- Others : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Mar 2014 | Others | ₹5.00 M | Open |
| 01 Jul 2016 | Others | ₹1.90 M | Satisfied |
| 04 Jun 2011 | State Bank Of India | ₹5.00 M | Satisfied |
| 13 Sep 2004 | State Bank Of India | ₹3.23 M | Satisfied |
| 14 Jan 1999 | Dena Bank | ₹0.15 M | Satisfied |
How Many Employees Work at Native Drugs?
Unlock and access historical data on people associated with Native Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Native Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Native Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.